Netherlands' Qiagen cuts 2026 sales and EPS outlook

Qiagen NV

27/04/2026 21:23

Overview

Netherlands molecular diagnostics firm's preliminary Q1 net sales rose 2% but fell 1% CER

Preliminary Q1 adjusted EPS was $0.54, in line with company outlook

Company cut full-year 2026 net sales growth and adjusted EPS guidance

Outlook

Qiagen cuts 2026 net sales growth outlook to about 1-2% CER from at least 5% CER

Company now expects 2026 adj diluted EPS of at least $2.43 CER, down from at least $2.50 CER

Qiagen expects Q2 2026 net sales to decline about 2% CER from $534 mln in Q2 2025

Result Drivers

QUANTIFERON DECLINE - QuantiFERON sales fell 5% CER, mainly due to a significant drop in immigration testing demand in the U.S. and Middle East

SAMPLE TECHNOLOGIES GROWTH - Sample technologies delivered 9% CER growth, driven by demand for automated consumables and instrument placements

U.S. LIFE SCIENCES CAUTION - Cautious demand from U.S. Life Sciences customers weighed on overall sales

Company press release: ID:nEQbkQVVfa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Adjusted EPS
$0.54


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Qiagen NV is €50.00, about 53.2% above its April 27 closing price of €32.64

The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 17 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)